Cargando…

Alternative Chelator for (89)Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)

[Image: see text] Zirconium-89 is an effective radionuclide for antibody-based positron emission tomography (PET) imaging because its physical half-life (78.41 h) matches the biological half-life of IgG antibodies. Desferrioxamine (DFO) is currently the preferred chelator for (89)Zr(4+); however, ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deri, Melissa A., Ponnala, Shashikanth, Zeglis, Brian M., Pohl, Gabor, Dannenberg, J. J., Lewis, Jason S., Francesconi, Lynn C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059252/ https://www.ncbi.nlm.nih.gov/pubmed/24814511 http://dx.doi.org/10.1021/jm500389b

Ejemplares similares

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

New Insights into Structure and Luminescence of Eu(III) and Sm(III) Complexes of the 3,4,3-LI(1,2-HOPO) Ligand
por: Daumann, Lena J., et al.
Publicado: (2015)

Folding Dynamics of 3,4,3-LI(1,2-HOPO) in Its Free and Bound State with U(4+) Implicated by MD Simulations
por: Wang, Qin, et al.
Publicado: (2022)

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
por: Roy, Jyoti, et al.
Publicado: (2021)

Evaluation of (89)Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET
por: Radaram, Bhasker, et al.
Publicado: (2023)

Novel Bifunctional Cyclic Chelator for (89)Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates
por: Zhai, Chuangyan, et al.
Publicado: (2015)

Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice
por: N.Tinianow, Jeff, et al.
Publicado: (2016)

Microfluidic Preparation of (89)Zr-Radiolabelled Proteins by Flow Photochemistry
por: Earley, Daniel F., et al.
Publicado: (2021)

(89)Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
por: Chang, Albert J., et al.
Publicado: (2012)

PET Imaging of Small Extracellular Vesicles via [(89)Zr]Zr(oxinate)(4) Direct Radiolabeling
por: Khan, Azalea A., et al.
Publicado: (2022)

Automated light-induced synthesis of (89)Zr-radiolabeled antibodies for immuno-positron emission tomography
por: Klingler, Simon, et al.
Publicado: (2022)

Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89
por: Zhai, Chuangyan, et al.
Publicado: (2019)

(66)Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?
por: Amor-Coarasa, Alejandro, et al.
Publicado: (2018)

One-step, kit-based radiopharmaceuticals for molecular SPECT imaging: a versatile diphosphine chelator for (99m)Tc radiolabelling of peptides
por: Hungnes, Ingebjørg N., et al.
Publicado: (2021)

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
por: Fani, Melpomeni, et al.
Publicado: (2022)

Radiolabelling of Polyclonally Expanded Human Regulatory T Cells (Treg) with (89)Zr-oxine for Medium-Term In Vivo Cell Tracking
por: Jacob, Jacinta, et al.
Publicado: (2023)

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
por: Perk, Lars R., et al.
Publicado: (2009)

(89)Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
por: Fung, Kimberly, et al.
Publicado: (2020)

Radiolabeled tirofiban – a potential radiopharmaceutical for detection of deep venous thrombosis
por: Darkovska-Serafimovska, Marija, et al.
Publicado: (2016)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

A Brief Review of Chelators for Radiolabeling Oligomers
por: Liu, Yuxia, et al.
Publicado: (2010)

Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of (89)Zr Immune-PET Tracers
por: Imura, Ryota, et al.
Publicado: (2021)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET
por: Chomet, Marion, et al.
Publicado: (2020)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
por: Lahnif, Hanane, et al.
Publicado: (2021)

Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals
por: Davey, Patrick R. W. J., et al.
Publicado: (2022)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of (89)Zr-DFO-Pertuzumab
por: Vivier, Delphine, et al.
Publicado: (2020)

Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability
por: Kang, Chi Soo, et al.
Publicado: (2022)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Side-by-Side Comparison of Five Chelators for (89)Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability
por: Damerow, Helen, et al.
Publicado: (2021)

Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling
por: Tsionou, Maria Iris, et al.
Publicado: (2017)

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
por: Mostafa, Ahmed M. A., et al.
Publicado: (2023)

Click-to-Chelate: Development of Technetium and Rhenium-Tricarbonyl Labeled Radiopharmaceuticals
por: Kluba, Christiane A., et al.
Publicado: (2013)

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
por: Fersing, Cyril, et al.
Publicado: (2022)

Recent Advances in Zirconium-89 Chelator Development
por: Bhatt, Nikunj B., et al.
Publicado: (2018)

The Race for Hydroxamate-Based Zirconium-89 Chelators
por: Feiner, Irene V. J., et al.
Publicado: (2021)

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET
por: Vugts, Danielle J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rlhnlfrdmki5ka7bck0k519q5v